Phosphorylation and ubiquitination of degron proximal residues are essential for class II transactivator (CIITA) transactivation and major histocompatibility class II expression.

Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol (2011) 4.31

Regulation of major histocompatibility complex class II genes. Curr Opin Immunol (2010) 1.15

A mental retardation-linked nonsense mutation in cereblon is rescued by proteasome inhibition. J Biol Chem (2013) 0.88

Expression regulation of major histocompatibility complex class I and class II encoding genes. Front Immunol (2011) 0.85

Proteomic identification of protein ubiquitination events. Biotechnol Genet Eng Rev (2013) 0.81

The class II transactivator (CIITA) is regulated by post-translational modification cross-talk between ERK1/2 phosphorylation, mono-ubiquitination and Lys63 ubiquitination. Biosci Rep (2015) 0.78

Degradation, Promoter Recruitment and Transactivation Mediated by the Extreme N-Terminus of MHC Class II Transactivator CIITA Isoform III. PLoS One (2016) 0.76

Pulling a Ligase out of a "HAT": pCAF Mediates Ubiquitination of the Class II Transactivator. Int J Cell Biol (2017) 0.75

Protein arginine methyltransferase 1 (PRMT1) represses MHC II transcription in macrophages by methylating CIITA. Sci Rep (2017) 0.75

The ubiquitination of the influenza A virus PB1-F2 protein is crucial for its biological function. PLoS One (2015) 0.75

Development of potent class II transactivator gene delivery systems capable of inducing de novo MHC II expression in human cells, in vitro and ex vivo. Gene Ther (2017) 0.75

Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature (2002) 10.96

Structure of a beta-TrCP1-Skp1-beta-catenin complex: destruction motif binding and lysine specificity of the SCF(beta-TrCP1) ubiquitin ligase. Mol Cell (2003) 5.31

Regulation of major histocompatibility complex class-II genes: X, Y and other letters of the alphabet. Annu Rev Immunol (1990) 3.68

Sequences and factors: a guide to MHC class-II transcription. Annu Rev Immunol (1992) 3.61

Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J (1997) 2.52

CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. Genes Dev (2000) 2.19

CIITA-regulated plexin-A1 affects T-cell-dendritic cell interactions. Nat Immunol (2003) 2.13

A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation. PLoS One (2006) 2.05

Acetylation by PCAF enhances CIITA nuclear accumulation and transactivation of major histocompatibility complex class II genes. Mol Cell Biol (2000) 1.95

Cyclin D1 gene (CCND1) mutations in endometrial cancer. Oncogene (2003) 1.74

The use of TaqMan RT-PCR assays for semiquantitative analysis of gene expression in CNS tissues and disease models. J Neurosci Methods (2000) 1.70

Interferon-gamma induces major histocompatibility class II transactivator (CIITA), which mediates collagen repression and major histocompatibility class II activation by human aortic smooth muscle cells. Circ Res (2006) 1.64

The F box protein Fbx6 regulates Chk1 stability and cellular sensitivity to replication stress. Mol Cell (2009) 1.64

Polymorphisms in CLEC16A and CIITA at 16p13 are associated with primary adrenal insufficiency. J Clin Endocrinol Metab (2008) 1.51

Two distinct gamma interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT1, interferon regulatory factor 1, and transforming growth factor beta. Mol Cell Biol (1999) 1.50

A defect in the nuclear translocation of CIITA causes a form of type II bare lymphocyte syndrome. Immunity (1999) 1.31

MHC class II transactivator inhibits IL-4 gene transcription by competing with NF-AT to bind the coactivator CREB binding protein (CBP)/p300. J Immunol (2000) 1.22

Enhancement of CIITA transcriptional function by ubiquitin. Nat Immunol (2003) 1.18

Enhanced production of IL-10 by dendritic cells deficient in CIITA. J Immunol (2005) 1.09

Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition. J Pathol (2009) 1.09

Physical and functional interactions of monoubiquitylated transactivators with the proteasome. J Biol Chem (2008) 1.08

Mechanisms of nuclear import and export that control the subcellular localization of class II transactivator. J Immunol (2001) 1.07

Phosphorylation of CIITA directs its oligomerization, accumulation and increased activity on MHCII promoters. EMBO J (2002) 1.05

Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells. Oncogene (2004) 1.04

Transforming growth factor beta (TGFbeta)-induced apoptosis: the rise & fall of Bim. Cell Cycle (2009) 1.04

Class II major histocompatibility complex transactivator (CIITA) inhibits matrix metalloproteinase-9 gene expression. J Biol Chem (2004) 1.03

The 19S proteasome ATPase Sug1 plays a critical role in regulating MHC class II transcription. Mol Immunol (2008) 1.02

Phosphorylation of class II transactivator regulates its interaction ability and transactivation function. Int Immunol (2003) 1.02

Downregulation of CIITA function by protein kinase a (PKA)-mediated phosphorylation: mechanism of prostaglandin E, cyclic AMP, and PKA inhibition of class II major histocompatibility complex expression in monocytic lines. Mol Cell Biol (2001) 1.01

Regulation of acetylation at the major histocompatibility complex class II proximal promoter by the 19S proteasomal ATPase Sug1. Mol Cell Biol (2008) 1.00

N-terminal destruction signals lead to rapid degradation of the major histocompatibility complex class II transactivator CIITA. Eur J Immunol (2003) 0.98

Cathepsin E: a novel target for regulation by class II transactivator. J Immunol (2004) 0.98

Cutting edge: the class II transactivator prevents activation-induced cell death by inhibiting Fas ligand gene expression. J Immunol (2001) 0.98

CIITA mediates interferon-gamma repression of collagen transcription through phosphorylation-dependent interactions with co-repressor molecules. J Biol Chem (2007) 0.97

Activation domain-dependent monoubiquitylation of Gal4 protein is essential for promoter binding in vivo. J Biol Chem (2008) 0.96

MHC II molecules in inflammatory diseases: interplay of qualities and quantities. Trends Immunol (2005) 0.95

Serine residues 286, 288, and 293 within the CIITA: a mechanism for down-regulating CIITA activity through phosphorylation. J Immunol (2004) 0.95

Regulating the activity of class II transactivator by posttranslational modifications: exploring the possibilities. Mol Cell Biol (2009) 0.93

Epigenetic silencing of MHC2TA transcription in cancer. Biochem Pharmacol (2006) 0.91

Identification of MHC class II-restricted tumor antigens recognized by CD4+ T cells. Methods (2003) 0.90

Mitogen-activated protein kinase ERK1/2 regulates the class II transactivator. J Biol Chem (2008) 0.89

Sequential modifications in class II transactivator isoform 1 induced by lipopolysaccharide stimulate major histocompatibility complex class II transcription in macrophages. J Biol Chem (2006) 0.88

Lysine 269 is essential for cyclin D1 ubiquitylation by the SCF(Fbx4/alphaB-crystallin) ligase and subsequent proteasome-dependent degradation. Oncogene (2009) 0.84

Cellular and gene therapy for major histocompatibility complex class II deficiency. News Physiol Sci (2004) 0.78

Association of the 19S proteasomal ATPases with the ATPase-binding domain of CIITA is essential for CIITA stability and MHC class II expression. Immunol Cell Biol (2010) 0.77